Senhwa is a precision therapy company focusing on developing First-in-Class therapeutics for patients with unmet medical needs. These include multiple programs for gene-mutated cancers, rare diseases, and novel coronaviruses.
Senhwa’s Pidnarulex (CX-5461) has proven to be the next generation DDR (DNA Damage Response) drug, with the mechanism of synthetic lethality across multiple tumor types in patients with loss of function of tumor suppressor genes such as HRD (Homologous Recombination Deficiency) and beyond, and has great potential for patients who have developed resistance to PARP inhibitors and platinum or other chemotherapies.
Dr. John Soong is a board certified physician with specialty training in Clinical Pathology and a Fellow of the College of American Pathologists (FCAP). His experiences in patient care as well as expertise in diagnosing a broad spectrum of human diseases through the understanding of disease mechanisms brings insights to novel drug target identification.